Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.

Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner PR, Li Y, Wei X, Chopra R, Hege K, DiMartino J, Shih K.

Clin Cancer Res. 2019 Jan 1;25(1):90-98. doi: 10.1158/1078-0432.CCR-18-1203. Epub 2018 Sep 10.

PMID:
30201761
2.

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, Lopez-Girona A, Cai T, Pourdehnad M, Trotter M, Daniel TO, Schafer PH, Klippel A, Thakurta A, Chopra R, Gandhi AK.

Blood. 2015 Aug 6;126(6):779-89. doi: 10.1182/blood-2015-02-628669. Epub 2015 May 22.

3.

Investigating Myc-dependent translational regulation in normal and cancer cells.

Cunningham JT, Pourdehnad M, Stumpf CR, Ruggero D.

Methods Mol Biol. 2013;1012:201-12. doi: 10.1007/978-1-62703-429-6_13.

4.

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.

Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11988-93. doi: 10.1073/pnas.1310230110. Epub 2013 Jun 26. Erratum in: Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):1760.

5.

Reduced grey matter metabolism due to white matter edema allows optimal assessment of brain tumors on 18F-FDG-PET.

Pourdehnad M, Basu S, Duarte P, Okpaku AS, Saboury B, Hustinx R, Alavi A.

Hell J Nucl Med. 2011 Sep-Dec;14(3):219-23.

6.

Stability of cerebral blood flow measures using a split-dose technique with (99m)Tc-exametazime SPECT.

Newberg AB, Saffer J, Farrar J, Pourdehnad M, Alavi A.

Nucl Med Commun. 2005 May;26(5):475-8.

PMID:
15838432
7.

18F-FDG PET in malignant lymphoma: significance of positive findings.

Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S.

Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):749-56. Epub 2005 Mar 23.

PMID:
15785956
8.

PET imaging for differentiating recurrent brain tumor from radiation necrosis.

Hustinx R, Pourdehnad M, Kaschten B, Alavi A.

Radiol Clin North Am. 2005 Jan;43(1):35-47. Review.

PMID:
15693646
9.

Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.

Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS.

J Neurooncol. 2004 May;68(1):1-9.

PMID:
15174514
10.

Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents.

Schmitz A, Shiue CY, Feng Q, Shiue GG, Deng S, Pourdehnad MT, Schirrmacher R, Vatamaniuk M, Doliba N, Matschinsky F, Wolf B, Rösch F, Naji A, Alavi AA.

Nucl Med Biol. 2004 May;31(4):483-91. Erratum in: Nucl Med Biol. 2005 Feb;32(2):209.

PMID:
15093819
11.

Cerebral blood flow during meditative prayer: preliminary findings and methodological issues.

Newberg A, Pourdehnad M, Alavi A, d'Aquili EG.

Percept Mot Skills. 2003 Oct;97(2):625-30.

PMID:
14620252
12.

Inter-modality comparisons of seizure focus lateralization in complex partial seizures.

Meyer PT, Cortés-Blanco A, Pourdehnad M, Levy-Reis I, Desiderio L, Jang S, Alavi A.

Eur J Nucl Med. 2001 Oct;28(10):1529-40.

PMID:
11685497
13.

Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?

Zhuang HM, Cortés-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martínez-Lázaro R, Lee JH, Loman JC, Rossman MD, Alavi A.

Nucl Med Commun. 2001 Oct;22(10):1123-8.

PMID:
11567186
14.

Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.

Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, Mozley PD, Rossman MD, Albelda SM, Alavi A.

J Nucl Med. 2001 Sep;42(9):1412-7.

15.

Similar pelvic abnormalities on FDG positron emission tomography of different origins.

Zhuang H, Yamamoto AJ, Sinha P, Pourdehnad M, Liu Y, Alavi A.

Clin Nucl Med. 2001 Jun;26(6):515-7.

PMID:
11353298
16.

Intense F-18 fluorodeoxyglucose uptake caused by mycobacterium avium intracellulare infection.

Zhuang H, Pourdehnad M, Yamamoto AJ, Rossman MD, Alavi A.

Clin Nucl Med. 2001 May;26(5):458. No abstract available.

PMID:
11317033
17.

The measurement of regional cerebral blood flow during the complex cognitive task of meditation: a preliminary SPECT study.

Newberg A, Alavi A, Baime M, Pourdehnad M, Santanna J, d'Aquili E.

Psychiatry Res. 2001 Apr 10;106(2):113-22.

PMID:
11306250
18.

The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants.

Zhuang H, Duarte PS, Pourdehnad M, Maes A, Van Acker F, Shnier D, Garino JP, Fitzgerald RH, Alavi A.

J Nucl Med. 2001 Jan;42(1):44-8.

19.

26. Incidental findings should be included in the analysis of cost-effectiveness for evaluation of pulmonary nodules by FDG-PET.

Zhuang HM, Duarte P, Pourdehnad M, Yamamoto AJ, Loman JC, Sinha P, Alavi A.

Clin Positron Imaging. 2000 Jul;3(4):180.

PMID:
11150783
20.

The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.

Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A.

Nucl Med Commun. 2000 Sep;21(9):793-8.

PMID:
11065150
21.

Gastric emptying of solids: estimates of lag phase and constant emptying times.

Couturier O, Le Rest C, Gournay J, Pourdehnad M, Bridji B, Turzo A, Bizais Y.

Nucl Med Commun. 2000 Jul;21(7):665-75.

PMID:
10994671
22.

Standardized uptake value as an unreliable index of renal disease on fluorodeoxyglucose PET imaging.

Zhuang H, Duarte PS, Pourdehnad M, Li P, Alavi A.

Clin Nucl Med. 2000 May;25(5):358-60.

PMID:
10795695
23.

Muscarinic blockade inhibits gastric emptying of mixed-nutrient meal: effects of weight and gender.

Teff KL, Alavi A, Chen J, Pourdehnad M, Townsend RR.

Am J Physiol. 1999 Mar;276(3):R707-14. doi: 10.1152/ajpregu.1999.276.3.R707.

PMID:
10070130
24.

Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.

Cesano A, Wortman JA, Pourdehnad M, Visonneau S, Mozley D, Bhatnagar A, Alavi A, Santoli D.

Int J Oncol. 1999 Feb;14(2):233-44.

PMID:
9917497

Supplemental Content

Loading ...
Support Center